SPRO:NASDAQSpero Therapeutics, Inc. Analysis

The stock is trading at $1.21, well below its 20‑day SMA of $1.90 and 50‑day SMA of $2.35, indicating a bearish price gap. RSI sits at 19.7, placing the shares in oversold territory and suggesting a potential rebound. MACD shows a bearish divergence with the line below the signal, reinforcing short‑term downside pressure. Volatility is extreme at 124% over the past 30 days and beta of 1.44, meaning the stock moves sharply with the market. Yet the valuation metrics are compelling: a trailing P/E of 4.48 versus an industry average of 28.97 and a DCF fair value of $3.88 imply more than 200% upside. The balance sheet is strong, with $56.1 M cash, minimal debt, and positive free cash flow, providing a runway for ongoing trials.
Recent material news includes a $105 M non‑dilutive royalty financing deal and plans to launch a Phase 2 trial of SP001 in Q2 2027 for IgG4‑related disease, which could unlock significant milestone payments. The company’s operating margins remain negative and earnings are volatile, reflecting its clinical‑stage status. The current support level at $1.19 aligns with the 52‑week low, offering a technical floor but also a barrier to upside. With the market sentiment at “Extreme Greed,” investors may be underpricing the upside from the pipeline. Given the juxtaposition of deep discount, cash cushion, and upcoming catalysts, the stock presents a speculative upside opportunity while still bearing high execution risk.